Antibodies against human CSF-1R and uses thereof
The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
1. An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 25, a CDR2 region comprising SEQ ID NO: 26, and a CDR1 region comprising SEQ ID NO: 27, and the light chain variable domain comprises a CDR3 region comprising SEQ ID NO: 28, a CDR2 region comprising SEQ ID NO: 29, and a CDR1 region comprising SEQ ID NO: 30.
2. A pharmaceutical composition comprising the antibody according to claim 1 .
3. The pharmaceutical composition according to claim 2 , wherein the antibody is formulated in a pharmaceutically acceptable carrier.
4. The antibody according to claim 1 , wherein the antibody is of human IgG1 subclass or is of human IgG4 subclass.
5. The antibody according to claim 1 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.
6. A pharmaceutical composition comprising the antibody according to claim 5 .
7. The antibody according to claim 1 , wherein the antibody is an antigen binding fragment.
8. A pharmaceutical composition comprising the antibody according to claim 7 .
9. The antibody according to claim 1 , wherein the antibody is a monoclonal antibody.
10. A pharmaceutical composition comprising the antibody according to claim 9 .
11. An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises SEQ ID NO: 31 and the light chain variable domain comprises SEQ ID NO: 32.
12. A pharmaceutical composition comprising the antibody according to claim 11 .
13. The pharmaceutical composition according to claim 12 , wherein the antibody is formulated in a pharmaceutically acceptable carrier.
14. The antibody according to claim 11 , wherein the antibody is of human IgG1 subclass or is of human IgG4 subclass.
15. The antibody according to claim 11 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody.
16. A pharmaceutical composition comprising the antibody according to claim 15 .
17. The antibody according to claim 11 , wherein the antibody is an antigen binding fragment.
18. A pharmaceutical composition comprising the antibody according to claim 17 .
19. The antibody according to claim 11 , wherein the antibody is a monoclonal antibody.
20. A pharmaceutical composition comprising the antibody according to claim 19 .